McDonnell Boehnen Hulbert & Berghoff LLP partner Andrew Williams, Ph.D. is quoted in an article entitled, “Cautious Optimism for Biosimilars in Rheumatology” that appears in the December 27, 2016 online edition of MedPage Today. In April 2016, the FDA approved Inflectra, a biosimilar to infliximab (Remicade), which was the first monoclonal antibody biosimilar, and MedPage Today reported on the clinical and legal issues being faced. Here we review subsequent developments regarding biosimilars for rheumatic diseases. View the article